237 related articles for article (PubMed ID: 35098932)
21. Cellular senescence in the cholangiopathies.
Bogert PS; O'Hara SP; LaRusso NF
Curr Opin Gastroenterol; 2022 Mar; 38(2):121-127. PubMed ID: 35098933
[TBL] [Abstract][Full Text] [Related]
22. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation.
Labiano I; Agirre-Lizaso A; Olaizola P; Echebarria A; Huici-Izagirre M; Olaizola I; Esparza-Baquer A; Sharif O; Hijona E; Milkiewicz P; Milkiewicz M; González-Romero F; Aspichueta P; Monte MJ; Marin JJG; Vucur M; Luedde T; Marzioni M; Mann DA; Bujanda L; Rodrigues PM; Banales JM; Perugorria MJ
J Hepatol; 2022 Oct; 77(4):991-1004. PubMed ID: 35750136
[TBL] [Abstract][Full Text] [Related]
23. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
24. Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
Halilbasic E; Steinacher D; Trauner M
Dig Dis; 2017; 35(3):288-292. PubMed ID: 28249255
[TBL] [Abstract][Full Text] [Related]
25. Chronic cholestatic diseases.
Poupon R; Chazouillères O; Poupon RE
J Hepatol; 2000; 32(1 Suppl):129-40. PubMed ID: 10728800
[TBL] [Abstract][Full Text] [Related]
26. Chronic cholestatic liver diseases: clues from histopathology for pathogenesis.
Pollheimer MJ; Fickert P; Stieger B
Mol Aspects Med; 2014 Jun; 37():35-56. PubMed ID: 24141039
[TBL] [Abstract][Full Text] [Related]
27. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
28. Farnesoid X receptor antagonizes macrophage-dependent licensing of effector T lymphocytes and progression of sclerosing cholangitis.
Shi T; Malik A; Yang Vom Hofe A; Matuschek L; Mullen M; Lages CS; Kudira R; Singh R; Zhang W; Setchell KDR; Hildeman D; Pasare C; Wagner B; Miethke AG
Sci Transl Med; 2022 Dec; 14(675):eabi4354. PubMed ID: 36516265
[TBL] [Abstract][Full Text] [Related]
29. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
30. Bile acid receptors in the biliary tree: TGR5 in physiology and disease.
Deutschmann K; Reich M; Klindt C; Dröge C; Spomer L; Häussinger D; Keitel V
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1319-1325. PubMed ID: 28844960
[TBL] [Abstract][Full Text] [Related]
31. P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.
Zhang J; Lyu Z; Li B; You Z; Cui N; Li Y; Li Y; Huang B; Chen R; Chen Y; Peng Y; Fang J; Wang Q; Miao Q; Tang R; Gershwin ME; Lian M; Xiao X; Ma X
Hepatology; 2023 Jul; 78(1):10-25. PubMed ID: 36799463
[TBL] [Abstract][Full Text] [Related]
32. Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.
Halilbasic E; Fuchs C; Hofer H; Paumgartner G; Trauner M
Dig Dis; 2015; 33 Suppl 2():149-63. PubMed ID: 26641242
[TBL] [Abstract][Full Text] [Related]
33. Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis.
Pollheimer MJ; Racedo S; Mikels-Vigdal A; Marshall D; Bowlus C; Lackner C; Madl T; Karlsen TH; Hov JR; Lyman SK; Adamkewicz J; Smith V; Moreau E; Zollner G; Eide TJ; Stojakovic T; Scharnagl H; Gruber HJ; Stauber RE; Trauner M; Fickert P
J Hepatol; 2018 Aug; 69(2):368-377. PubMed ID: 29709678
[TBL] [Abstract][Full Text] [Related]
34. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.
Jazrawi RP; de Caestecker JS; Goggin PM; Britten AJ; Joseph AE; Maxwell JD; Northfield TC
Gastroenterology; 1994 Jan; 106(1):134-42. PubMed ID: 8276175
[TBL] [Abstract][Full Text] [Related]
35. Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases
Nevens F; Trauner M; Manns MP
J Hepatol; 2023 Feb; 78(2):430-441. PubMed ID: 36272496
[TBL] [Abstract][Full Text] [Related]
36. Targeting FXR in Cholestasis.
Keitel V; Dröge C; Häussinger D
Handb Exp Pharmacol; 2019; 256():299-324. PubMed ID: 31201556
[TBL] [Abstract][Full Text] [Related]
37. ADAM Metalloproteinase Domain 17 Regulates Cholestasis-Associated Liver Injury and Sickness Behavior Development in Mice.
Almishri W; Swain LA; D'Mello C; Le TS; Urbanski SJ; Nguyen HH
Front Immunol; 2021; 12():779119. PubMed ID: 35095853
[TBL] [Abstract][Full Text] [Related]
38. Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
Yokoda RT; Carey EJ
Am J Gastroenterol; 2019 Oct; 114(10):1593-1605. PubMed ID: 31169523
[TBL] [Abstract][Full Text] [Related]
39. [Cholestatic liver diseases].
Reichel C; Meier-Abt PJ
Ther Umsch; 1997 Nov; 54(11):639-44. PubMed ID: 9454366
[TBL] [Abstract][Full Text] [Related]
40. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
